Article Text

Download PDFPDF

457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
  1. Martin Gutierrez1,
  2. Wei-Sen Lam2,
  3. Matthew Hellmann3,
  4. Matthew Gubens4,
  5. Charu Aggarwal5,
  6. Daniel Shao Weng Tan6,
  7. Enriqueta Felip7,
  8. Joanne WY Chiu8,
  9. Jong-Seok Lee9,
  10. James Chih-Hsin Yang10,
  11. Edward Garon11,
  12. Giovanna Finocchiaro12,
  13. Myung-Ju Ahn13,
  14. Alexander Luft14,
  15. Gregory Landers15,
  16. Andrea Basso16,
  17. Hua Ma16,
  18. Julie Kobie16,
  19. John Palcza16,
  20. Razvan Cristescu16,
  21. Lawrence Fong17,
  22. Alexandra Snyder16,
  23. Jianda Yuan16 and
  24. Roy Herbst18
  1. 1Hackensack University Medical Center, Hackensack, NJ, USA
  2. 2Fiona Stanley Hospital and Western Australia Country Health Service, Perth, Australia
  3. 3Memorial Sloan Kettering Cancer Center, New York, NY, USA
  4. 4University of California, San Francisco, San Francisco, CA, USA
  5. 5Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
  6. 6SingHealth Duke NUS Academic Medical, Singapore, Singapore
  7. 7Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain
  8. 8University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
  9. 9Seoul National University, Bundang Hospital, Seongnam, Korea, Republic of
  10. 10National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei City, Taiwan, Province of China
  11. 11David Geffen School of Medicine at UCLA, Santa Monica, USA
  12. 12IRCCS Humanitas Research Hospital, Milan, Italy
  13. 13Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Korea, Republic of
  14. 14Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation
  15. 15The Oncology Centre, KwaZulu-Natal, South Africa
  16. 16Merck and Co., Inc., Kenilworth, NJ, USA
  17. 17Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
  18. 18Comprehensive Cancer Center Yale School, New Haven, CT, USA


Background T-cell–inflamed gene expression profile (TcellinfGEP) and tumor mutational burden (TMB) are clinically validated biomarkers that independently predict pembrolizumab response. This study investigated prospective TcellinfGEP and TMB assessment in evaluating first-line pembrolizumab-based combination therapies; the different treatment combinations evaluated may provide insight into the unique biology of each biomarker subgroup.

Methods KEYNOTE-495/KeyImPaCT is a group-sequential, adaptively randomized, multisite, open-label, phase 2 study investigating first-line pembrolizumab plus the VEGF/FGFR inhibitor lenvatinib, CTLA-4 inhibitor quavonlimab (MK-1308), or LAG-3 inhibitor favezelimab (MK-4280) in patients with advanced NSCLC. DNA and RNA were extracted from tumor tissue to determine TcellinfGEP and TMB; patients were assigned to one of four biomarker-defined subgroups (TcellinfGEPlowTMBlow, TcellinfGEPlowTMBhigh, TcellinfGEPhighTMBlow, TcellinfGEPhighTMBhigh) and randomly assigned 1:1:1 to receive pembrolizumab (200mg IV Q3W)+lenvatinib (20mg oral QD), pembrolizumab+quavonlimab (75mg IV Q6W), or pembrolizumab+favezelimab (200mg [n=30] or 800mg [n=34] Q3W; the initial prespecified dose was 200mg but changed to 800mg based on emerging data). The primary end point was investigator-assessed ORR per RECIST v1.1. Multiple interim analyses will be performed until the prespecified clinical signal is observed. The first interim analysis for each combination therapy occurred after ≥10 patients had ≥12 weeks of follow-up.

Results At the data cutoff (January 11, 2021), 208 patients were treated (pembrolizumab+lenvatinib, n=72; pembrolizumab+quavonlimab, n=72; pembrolizumab+favezelimab 200mg, n=30; pembrolizumab+favezelimab 800mg, n=34). The overall assay success rate for testing and determining TcellinfGEP and TMB was 94%. In patients treated with pembrolizumab+lenvatinib, pembrolizumab+quavonlimab, or pembrolizumab+favezelimab, ORRs were generally highest in the TcellinfGEPhighTMBhigh subgroup (table 1); response rates were similar across combinations within this subgroup. ORR was low across combinations within the TcellinfGEPlowTMBlow subgroup. Treatment-related adverse events (TRAEs) occurred in 88%, 65%, 57%, and 59% of patients in the pembrolizumab+lenvatinib, pembrolizumab+quavonlimab, pembrolizumab+favezelimab 200mg and pembrolizumab+favezelimab 800mg arms, respectively. Consistent with the known TRAEs of these agents, most TRAEs were grade 1 or 2 in severity except in the pembrolizumab+lenvatinib arm (grade 3–5, 63%). Three deaths from TRAEs occurred (pembrolizumab+lenvatinib [n=2], brain hemorrhage and myocardial infarction; pembrolizumab+favezelimab 800 mg [n=1], pneumonitis).

Abstract 457 Table 1

Confirmed ORR by Therapy and Biomarker Status

Conclusions These data demonstrate the feasibility and clinical usefulness of prospective TcellinfGEP and TMB assessment to study the clinical activity of three first-line pembrolizumab-based combination therapies in patients with advanced NSCLC. Although sample sizes were small, the TcellinfGEPhighTMBhigh subgroup demonstrated the best response among the biomarker subgroups for all three combination therapies; further validation is needed to determine additional signals and may be addressed as more mature data become available.

Acknowledgements Jeanne Fahey, PhD, of Merck & Co., Inc., Kenilworth, New Jersey, USA, provided critical review of the abstract. Elisha Dettman PhD, Mark Ayers MS, and Andrey Loboda PhD of Merck & Co., Inc., Kenilworth, New Jersey, USA, provided critical review of study translational data. Medical writing and/or editorial assistance was provided by Shane Walton, PhD, and Lei Bai, PhD, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Trial Registration ClinicalTrials.

gov, NCT03516981

Ethics Approval The study protocol and all amendments were approved by the relevant institutional review board or ethics committee at each study site. All patients provided written informed consent to participate in the clinical trial.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.